LILLY ELI Stock Quote

$86.66 arrow  Change: 0.39 %Chge: 0.45% Vol: 292,409
End Of Day Prices
High: 87.02 | Low: 86.16 | Open: 86.3 | Close: 86.66
52 Wk High: 89.5 | 52 Wk Low: 73.83 | Todays Pivot: 86.61
Sector: Healthcare and Pharmaceuticals add stock to watch list

LLY Chart


You need Flash Player to see the chart, please download from the link below

Get Adobe Flash player

Related Healthcare and Pharmaceuticals Companies

Myriad Genetics 26.26 green arrow 45,449
Thermo Fisher Scientific 86.24 red arrow 205,916
Illumina 71.02 green arrow 86,228
Gilead Sciences 83.05 red arrow 622,791
Biogen Idec 115.64 red arrow 196,208
Regeneron Pharmaceuticals 304.29 green arrow 56,386
Merck 65.915 green arrow 542,887
Mylan 23.32 green arrow 4,588,200

Above is a small selection of related companies to Lilly Eli which compete alongside LLY within the Healthcare and Pharmaceuticals sector. To see more related companies to LLY, view our stock market today information page.

Online News For Lilly Eli

Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

Another Alzheimer’s candidate failed in clinical studies this week. An independent data monitoring committee (“IDMC”) recommended Lilly LLY and AstraZeneca AZN to discontinue two studies on lanabecestat. Shares of Israel-based small biotech, Galmed ...


Should You Be Tempted To Sell Eli Lilly and Company (NYSE:LLY) Because Of Its PE Ratio?

Eli Lilly and Company (NYSE:LLY) trades with a trailing P/E of 79.9x, which is higher than the industry average of 23.5x. While LLY might seem like a stock to avoid or sell if you own it, it is important to understand the assumptions behind the P/E ratio ...


Lilly (LLY) and AstraZeneca (AZN) Halt Phase 3 Trials of Lanabecestat for Alzheimer's Disease Due to Futility

Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease. The decision is based on ...


Lilly (LLY) to Unveil New Data at EULAR Furthering Commitment to Scientific Discovery in Immunology

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here. Eli Lilly and Company (NYSE: LLY) announced today it will present new data from its immunology portfolio, including cornerstone ...


Inside Trade: Lilly Endowment Inc Sold 11,104 Shares of Eli Lilly and Company (NYSE:LLY)

The insider of Lilly Eli & Co, Lilly Endowment Inc sold 11,104 shares of the corporation based on $86.3 per every share. These shares are worth based on the market about $957,953 US Dollars. Today, Lilly Endowment Inc has rights to 122.34 million shares or ...



Want To Add This Quote To Your Site?

With our stock widgets you can add a Lilly Eli quote to your website to keep your users up to date with the market. We have a variety of different styled widgets for LLY to choose from. Visit here to build your stock quote widget »